ALZN Alzamend Neuro Inc

P/E --
Forward P/E --
Price/Sales --
Beta 0.142
Div Yield --
Market Cap --

Company Analysis

Latest News

πŸ”΄ Alzamend Neuro is trading 15.61% down in pre-market after S-1 registration for up to 98,388,305 shares

Alzamend Neuro is trading 15.61% down now at $1.35 after investors reacted to an August 21, 2026 Form S-1 registration for Ault Lending’s resale of up to...

πŸ”΄ Alzamend Neuro is trading 6.86% down in pre-market amid dilution concerns

Alzamend Neuro is trading 6.86% down at $1.49, likely under pressure from dilution concerns tied to an August 21 registration filing. - The filing covers...

πŸ”΄ Alzamend Neuro is trading 6.2% down in after-hours trading amid possible dilution overhang

Alzamend Neuro is trading 6.2% down at $1.50 in after-hours trading, with potential resale shares issuable upon preferred-stock conversion creating a possible...

🟒 Alzamend Neuro is trading 6% up today amid broad biotech-sector strength

Alzamend Neuro is trading 6% up at $1.65, primarily supported by broad biotech-sector strength as XBI gains 2.06% during the August 25, 2026 session. - No new...

πŸ”΄ Alzamend Neuro is trading 6.41% down today after filing a 98.4 million-share resale registration

Alzamend Neuro is trading 6.41% down at $1.46 after filing a registration statement covering the resale of up to 98,388,305 common shares. - The shares may be...

Alzamend Neuro's Massive Share Offering Dwarfs Its Tiny Market Cap β€” Can the Stock Absorb the Blow?

Alzamend Neuro's Massive Share Offering Dwarfs Its Tiny Market Cap β€” Can the Stock Absorb the Blow?

Shares of Alzamend Neuro (ALZN) slid 7.1% to $1.45 on August 24, extending a volatile week after the clinical-stage biotech disclosed a shelf registration...

πŸ”΄ Alzamend Neuro is trading 7.05% down in pre-market amid selling-stockholder offering of up to 98,388,305 shares

Alzamend Neuro is trading 7.05% down in pre-market at $1.45 after a filing disclosed an offering of up to 98,388,305 shares by selling stockholders. - The...

πŸ”΄ Alzamend Neuro is trading 6.1% down today as XBI falls 2.47%

Alzamend Neuro is trading at $1.53, down -6.13%, amid biotech-sector weakness. - No negative company-specific announcement was identified for August 21,...

πŸ”΄ Alzamend Neuro is trading 8% down in pre-market after sharp after-hours reversal

Alzamend Neuro is trading at $1.50, down 7.96% after a sharp after-hours reversal. - The stock closed at $1.63 on August 20, 2026. - The latest company news...

πŸ”΄ Alzamend Neuro is trading 10.43% down in after-hours trading as major indexes fell

Alzamend Neuro is trading 10.43% down at $1.46, aligned with broad risk-off sentiment after the August 20, 2026 regular session closed at $1.63. - No negative...

πŸ”΄ Alzamend Neuro is trading 7.36% down in after-hours trading amid likely broad risk-off pressure

Alzamend Neuro is trading 7.36% down now at $1.51 in after-hours trading, as broader risk-off sentiment likely pressured the stock. - The stock closed August...

🟒 Alzamend Neuro is trading 6.59% up today after AL001 findings accepted for Neuroscience 2026 poster

Alzamend Neuro is trading 6.59% up at $1.62 after announcing on August 20, 2026, that its AL001 Phase 1/2A resting-state fMRI findings were accepted for poster...

🟒 Alzamend Neuro is trading 7.24% up in pre-market after cancer-vaccine results lifted biotech sentiment

Alzamend Neuro is trading 7.24% up now at $1.63 in pre-market after positive late-stage personalized cancer-vaccine results from Moderna and Merck lifted...

🟒 Alzamend Neuro rises 5.3% β€” Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results

With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...

πŸ”΄ Alzamend Neuro is trading 5.7% down in pre-market

Alzamend Neuro is trading at $1.49, a -5.70% change, and appears to be driven by extended-hours trading pressure after the August 17 close of $1.58. β€’ No...

πŸ”΄ Alzamend Neuro is trading 7.6% down in after-hours trading with no clear catalyst identified

Alzamend Neuro is trading 7.6% down at $1.46, with no clear company-specific catalyst identified for the after-hours decline. - Fell from the regular-session...

🟒 Alzamend Neuro is trading 5.5% up today

Alzamend Neuro is trading 5.5% up at $1.53, with no clear August 14, 2026 company-specific catalyst identified. - Recent coverage highlights an August 4...

πŸ”΄ Alzamend Neuro is trading 6.79% down in pre-market with no clear company-specific catalyst identified

Alzamend Neuro is trading 6.79% down now at $1.37 after no clear company-specific catalyst was identified for August 12, 2026. - The latest notable...

🟒 Alzamend Neuro is trading 5.3% up today as investors respond to financing

Alzamend Neuro is trading 5.3% up at $1.44 as investors continue responding to its recently announced financing. - The initial Series D convertible...

Alzamend Neuro Lands $7.5M Lifeline From an Affiliate Lender β€” But Can Convertible Preferred Stock Save a Company Worth Less Than the Cash It Just Raised?

Alzamend Neuro Lands $7.5M Lifeline From an Affiliate Lender β€” But Can Convertible Preferred Stock Save a Company Worth Less Than the Cash It Just Raised?

Shares of Alzamend Neuro (ALZN) jumped 7.5% to $1.44 after the clinical-stage biotech disclosed a financing deal that dwarfs its own market value β€” raising...